Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

Not only do GLP-1 receptor agonists reduce weight and A1c levels, but they also may improve cardiac parameters.

Expansion of Indications Beyond Diabetes - Ongoing research into GLP-1 agonists for conditions such as cardiovascular diseases and neurodegenerative disorders could expand market potential.

Ecnoglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, was significantly more effective than placebo for inducing weight loss in adults with overweight or obesity, based on data ...

Dr. Lei Qian from Innovent Biologics, stated, "Mazdutide represents the next-generation dual GCG/GLP-1 receptor agonist. Its clinical development has been made possible by pooling the collective ...

These data disclosed today further support our goal of developing a next-generation oral GLP-1 receptor agonist with enhanced pharmacokinetic properties, specifically a more consistent plasma ...

MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist ...

Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates ...

Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a dual GCG / GLP-1 receptor agonist, in China.